Position in ABVX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$835,125
+$295,705 QoQ
Shares Held
7,500
+87.5% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026NINE MASTS CAPITAL Ltd holds $7,147,037 across 35 Biotechnology names. ABVX ranks #3 (11.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APLS |
Apellis Pharmaceuticals, Inc.
|
97,478 | $3,921,539 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
11,010 | $1,070,722 | |
| 3 | ABVX |
Abivax S.A.
This page
|
7,500 | $835,125 | |
| 4 | GALT |
Galectin Therapeutics Inc
|
19,324 | $53,913 | |
| 5 | BMEA |
Biomea Fusion, Inc.
|
32,472 | $49,682 | |
| 6 | OTLK |
Outlook Therapeutics, Inc.
|
232,546 | $47,904 | |
| 7 | PRQR |
ProQR Therapeutics N.V.
|
29,518 | $47,819 | |
| 8 | LCTX |
Lineage Cell Therapeutics, Inc.
|
29,194 | $46,126 |
All Filings in ABVX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $835,125 | 7,500 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $539,420 | 4,000 | Shares | Sole | 2026-02-10 | |
| No filing history on record for this holder in this stock. | ||||||